0.63 USD
-0.03 (-4.43%)
At close: Jan 30, 2026
0.65 USD
+0.02 (+3.17%)
After Hours: 1/30/2026, 8:00:01 PM
CTSO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. CTSO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, CTSO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year CTSO has reported negative net income.
- In the past year CTSO has reported a negative cash flow from operations.
- In the past 5 years CTSO always reported negative net income.
- CTSO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- CTSO's Return On Assets of -23.14% is in line compared to the rest of the industry. CTSO outperforms 51.09% of its industry peers.
- CTSO has a worse Return On Equity (-117.35%) than 63.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.14% | ||
| ROE | -117.35% | ||
| ROIC | N/A |
ROA(3y)-50.29%
ROA(5y)-37.4%
ROE(3y)-134.62%
ROE(5y)-90.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- CTSO has a Gross Margin of 77.02%. This is amongst the best in the industry. CTSO outperforms 89.13% of its industry peers.
- CTSO's Gross Margin has been stable in the last couple of years.
- The Profit Margin and Operating Margin are not available for CTSO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 77.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.74%
GM growth 5Y0.03%
2. Health
2.1 Basic Checks
- CTSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, CTSO has more shares outstanding
- Compared to 5 years ago, CTSO has more shares outstanding
- CTSO has a worse debt/assets ratio than last year.
2.2 Solvency
- CTSO has an Altman-Z score of -8.70. This is a bad value and indicates that CTSO is not financially healthy and even has some risk of bankruptcy.
- The Altman-Z score of CTSO (-8.70) is worse than 76.09% of its industry peers.
- CTSO has a Debt/Equity ratio of 1.61. This is a high value indicating a heavy dependency on external financing.
- CTSO's Debt to Equity ratio of 1.61 is on the low side compared to the rest of the industry. CTSO is outperformed by 79.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.61 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.7 |
ROIC/WACCN/A
WACC11.1%
2.3 Liquidity
- CTSO has a Current Ratio of 2.11. This indicates that CTSO is financially healthy and has no problem in meeting its short term obligations.
- CTSO's Current ratio of 2.11 is in line compared to the rest of the industry. CTSO outperforms 41.30% of its industry peers.
- CTSO has a Quick Ratio of 1.71. This is a normal value and indicates that CTSO is financially healthy and should not expect problems in meeting its short term obligations.
- With a Quick ratio value of 1.71, CTSO perfoms like the industry average, outperforming 47.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.11 | ||
| Quick Ratio | 1.71 |
3. Growth
3.1 Past
- CTSO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.35%, which is quite impressive.
- The Revenue has decreased by -8.97% in the past year.
- The Revenue has been growing slightly by 7.36% on average over the past years.
EPS 1Y (TTM)51.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-8.97%
Revenue growth 3Y-6.23%
Revenue growth 5Y7.36%
Sales Q2Q%1.01%
3.2 Future
- The Earnings Per Share is expected to grow by 22.52% on average over the next years. This is a very strong growth
- Based on estimates for the next years, CTSO will show a very strong growth in Revenue. The Revenue will grow by 26.86% on average per year.
EPS Next Y55.26%
EPS Next 2Y-173.17%
EPS Next 3Y22.52%
EPS Next 5YN/A
Revenue Next Year-3.2%
Revenue Next 2Y2.63%
Revenue Next 3Y8.04%
Revenue Next 5Y26.87%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- CTSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year CTSO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- CTSO's earnings are expected to grow with 22.52% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-173.17%
EPS Next 3Y22.52%
5. Dividend
5.1 Amount
- No dividends for CTSO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
CYTOSORBENTS CORP / CTSO FAQ
What is the fundamental rating for CTSO stock?
ChartMill assigns a fundamental rating of 2 / 10 to CTSO.
What is the valuation status of CYTOSORBENTS CORP (CTSO) stock?
ChartMill assigns a valuation rating of 1 / 10 to CYTOSORBENTS CORP (CTSO). This can be considered as Overvalued.
How profitable is CYTOSORBENTS CORP (CTSO) stock?
CYTOSORBENTS CORP (CTSO) has a profitability rating of 1 / 10.
Can you provide the financial health for CTSO stock?
The financial health rating of CYTOSORBENTS CORP (CTSO) is 2 / 10.